UMANA Pablo (CH),УМАНА Пабло (CH),KLAJN Kristian (CH),КЛАЙН Кристиан (CH),NIKOLINI Valeriya G. (CH),НИКОЛИНИ Валерия Г. (CH)
申请号：
RU2017110279
公开号：
RU0002710354C2
申请日:
2015.08.25
申请国别(地区):
RU
年份:
2019
代理人:
摘要：
FIELD: biotechnology.SUBSTANCE: invention relates to the field of biotechnology. Described is a group of inventions involving the use of a malignant tumour-immunocytokine, containing a version of IL-2, and an antibody which binds to human PD-L1, for treating cancer or for preventing or treating metastases, using a combination of a malignant tumour-immunocytokine containing a variant IL-2, and an antibody which binds to human PD-L1, to inhibit the growth of a malignant tumour which expresses a target for immunocytokine, and/or increasing the median and/or overall survival of individuals having a malignant tumour expressing a target for immunocytokine, using a combination of a carcinoembiral antigen (CEA)-indeed immunocytokine containing an IL-2 variant, and an antibody which binds to a human fibroblast activating protein (PD-L1), for inhibiting growth of a malignant tumour which expresses CEA, and/or increasing the median and/or overall survival of individuals having a malignant CEA-expressing tumour, using a combination of a fibroblast activating protein (FAP) -based immunocytokine comprising an IL-2 variant, and an antibody which binds to human PD-L1, for inhibiting the growth of a malignant tumour which expresses FAP, and/or increasing the median and/or overall survival of individuals having a malignant tumour expressing FAP, a combination of a malignant tumour-bound immunocytokine comprising a variant IL-2, and an antibody which binds to human PD-L1 for treating cancer, a combination of a malignant tumour-immunocytokine containing an IL-2 variant, and an antibody which binds to human PD-L1, for treating a patient having a CEA-expressing malignant tumour or malignant tumour, characterized by expression or overexpression of CEA having a FAP-expressing malignant tumour or a malignant tumour characterized by FAP expression or overexpression, or a malignant tumour associated with CEA or FAP expression or overexpression.EFFECT: invention expands the arsenal of cancer t
